Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV criteria for anorexia nervosa, including weight \<85% of ideal body weight (IBW) and amenorrhea for three months;~* Age 18-45 years old;~* Gastrointestinal tract symptoms;~* Non-hormonal method of birth control, which must be used throughout the study. Female patients unable to bear children must have this documented (i.e., tubal ligation, hysterectomy, or post-menopausal, defined as a minimum of one year since the last menstrual period and elevated FSH);~* Stable concomitant medications defined as no changes in regimen for at least 2 weeks prior to baseline;~* Able to provide written informed consent prior to any study procedures and be willing and able to comply with study procedures, including daily SC injections and completion of a daily injection log.~* Patient has a primary care physician or treatment team managing her care.~Exclusion Criteria:~* Use of hormone therapy (including but not limited to estrogen, progesterone) or hormonal methods of birth control (i.e., oral, implantable, or injectable) within eight weeks of screening; or Depo-Provera within six months of screening;~* Pregnancy, lactation or breastfeeding, or a positive serum or urine pregnancy test, within eight weeks of screening;~* History of diabetes mellitus;~* History of purging behaviors greater than once monthly within the last three months;~* Active substance abuse;~* Use of metoclopramide, erythromycin, 5HT3 anti-emetics, or opioid medications within 2 weeks prior to baseline. \[Note: these drugs should also not be used post-baseline\];~* Hematocrit \< 30.0 %, hemoglobin \< 10.0 g/dl, potassium \< 3.0 mmol/L, fasting glucose \> 100 mg/dL, creatinine \> 1.5 mg/dL, AST or ALT \> 1.5 times the upper limit of normal, or abnormal plasma thyroid stimulating hormone (TSH) level;~* Currently receiving parenteral feeding or enteral feeding, or presence of a nasogastric or other enteral tube for feeding or decompression;~* History of gastric surgery such as fundoplication, gastrectomy, gastric pacemaker placement, vagotomy, bariatric procedure, small or large bowel resection;~* Clinical suspicion, in the opinion of the investigator, of active or symptomatic peptic ulcer disease, cholelithiasis, colitis, celiac sprue, or inflammatory bowel disease;~* Active suicidal ideation;~* Beck Depression Inventory-2 score of ≥ 29;~* Current inpatient hospitalization;~* Allergic or intolerant of egg, milk, wheat or algae, as these are components of the GEBT test meal;~* Participation in a clinical study with an investigational medication or device within the 30 days prior to dosing in the present study;~* Any other reason, which in the opinion of the Investigator, including severe renal, hepatic or cardiac disease, would confound proper interpretation of the study or expose a patient to unacceptable risk.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- RM-131 (Type: ACTIVE_COMPARATOR): Active study drug - RM-131
- Placebo (Type: PLACEBO_COMPARATOR): Placebo comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).